公开(公告)号：US20230023075A1

公开(公告)日：2023-01-26

申请号：US17694829

申请日：2022-03-15

申请人： CHEMOCENTRYX, INC.

发明人： James J. CAMPBELL ,  Zhenhua MIAO ,  Thomas J. SCHALL ,  Israel CHARO ,  Shijie LI ,  Christine Marie JANSON ,  Rajinder SINGH ,  Karen EBSWORTH

IPC分类号： A61K31/536 ,  A61P35/00 ,  A61K31/165 ,  A61K31/357 ,  A61K45/06

摘要： The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.

公开(公告)号：US20220280481A1

公开(公告)日：2022-09-08

申请号：US17527939

申请日：2021-11-16

申请人： CHEMOCENTRYX, INC.

发明人： James J. CAMPBELL ,  Karen EBSWORTH ,  Antoni KRASINSKI ,  Venkat Reddy MALI ,  Jeffrey McMAHON ,  Rajinder SINGH ,  Ju YANG ,  Chao YU ,  Penglie ZHANG

IPC分类号： A61K31/4035 ,  A61P29/00 ,  A61P17/06

摘要： The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

公开(公告)号：US20210322410A1

公开(公告)日：2021-10-21

申请号：US17328293

申请日：2021-05-24

申请人： ChemoCentryx, Inc.

发明人： James CAMPBELL ,  Israel CHARO ,  Thomas SCHALL ,  Karen EBSWORTH ,  Yu WANG ,  Yibin ZENG ,  Penglie ZHANG ,  Joanne TAN

IPC分类号： A61K31/502 ,  A61K31/4412 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/415 ,  A61K31/5377 ,  A61K39/395 ,  C07K16/28 ,  A61P1/00

摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.

公开(公告)号：US20190209527A1

公开(公告)日：2019-07-11

申请号：US16241469

申请日：2019-01-07

申请人： CHEMOCENTRYX, INC.

发明人： James J. CAMPBELL ,  Karen EBSWORTH ,  Antoni KRASINSKI ,  Venkat Reddy MALI ,  Jeffrey McMAHON ,  Rajinder SINGH ,  Ju YANG ,  Chao YU ,  Penglie ZHANG

IPC分类号： A61K31/4035 ,  A61P17/06 ,  A61P29/00

CPC分类号： A61K31/4035 ,  A61P17/06 ,  A61P29/00

摘要： The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

公开(公告)号：US20160095921A1

公开(公告)日：2016-04-07

申请号：US14875506

申请日：2015-10-05

申请人： ChemoCentryx, Inc.

发明人： Karen EBSWORTH ,  Yu WANG ,  Yibin ZENG ,  Penglie ZHANG ,  Joanne TAN

IPC分类号： A61K39/395 ,  A61K31/4709 ,  A61K31/502 ,  A61K31/415 ,  A61K31/5377 ,  A61K31/4412 ,  A61K31/517

摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.

摘要翻译： 本文提供了在有需要的哺乳动物中治疗炎症性肠病（IBD）如克罗恩病和溃疡性结肠炎的组合物，方法和试剂盒。 该方法包括向患有IBD的受试者施用含有治疗有效量的趋化因子受体9（CCR9）抑制剂化合物和治疗有效量的抗α4和bgr7整联蛋白抗体如维多珠单抗的联合疗法。 本文还提供了包含CCR9抑制剂化合物和抗α4和bgr7整联蛋白抗体的试剂盒。